1. Home
  2. UTHR vs RBC Comparison

UTHR vs RBC Comparison

Compare UTHR & RBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • RBC
  • Stock Information
  • Founded
  • UTHR 1996
  • RBC 1919
  • Country
  • UTHR United States
  • RBC United States
  • Employees
  • UTHR N/A
  • RBC N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • RBC Metal Fabrications
  • Sector
  • UTHR Health Care
  • RBC Industrials
  • Exchange
  • UTHR Nasdaq
  • RBC Nasdaq
  • Market Cap
  • UTHR 13.8B
  • RBC 12.6B
  • IPO Year
  • UTHR 1999
  • RBC 2005
  • Fundamental
  • Price
  • UTHR $303.96
  • RBC $389.78
  • Analyst Decision
  • UTHR Buy
  • RBC Buy
  • Analyst Count
  • UTHR 13
  • RBC 6
  • Target Price
  • UTHR $382.00
  • RBC $411.00
  • AVG Volume (30 Days)
  • UTHR 694.7K
  • RBC 177.6K
  • Earning Date
  • UTHR 10-29-2025
  • RBC 08-01-2025
  • Dividend Yield
  • UTHR N/A
  • RBC N/A
  • EPS Growth
  • UTHR 17.94
  • RBC 17.43
  • EPS
  • UTHR 25.63
  • RBC 7.97
  • Revenue
  • UTHR $3,077,800,000.00
  • RBC $1,666,000,000.00
  • Revenue This Year
  • UTHR $13.89
  • RBC $13.30
  • Revenue Next Year
  • UTHR $5.68
  • RBC $10.09
  • P/E Ratio
  • UTHR $11.89
  • RBC $48.91
  • Revenue Growth
  • UTHR 17.62
  • RBC 5.48
  • 52 Week Low
  • UTHR $266.98
  • RBC $272.50
  • 52 Week High
  • UTHR $417.82
  • RBC $416.33
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 52.97
  • RBC 44.62
  • Support Level
  • UTHR $302.19
  • RBC $388.58
  • Resistance Level
  • UTHR $312.44
  • RBC $405.83
  • Average True Range (ATR)
  • UTHR 6.59
  • RBC 7.80
  • MACD
  • UTHR -0.48
  • RBC -1.29
  • Stochastic Oscillator
  • UTHR 60.65
  • RBC 11.94

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About RBC RBC Bearings Incorporated

RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: